SpyGlass Pharma, Inc. income statement SGP

It recorded a net loss of $19.9 million. Diluted earnings per share were -$0.59.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Research and development
—
11
9
Selling, general and administrative
—
11
7
Operating income
—
-22
-15
Interest income
—
2
2
Pretax income
—
-20
-14
Income tax
—
0
0
Net income
—
-20
-14
Basic EPS
—
-0.59
-0.69
Diluted EPS
—
-0.59
-0.69
Weighted average shares, basic
—
33
20
Weighted average shares, diluted
—
33
20
Other measures
Depreciation and amortization
—
0
0
EBITDA
—
-22
-15
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
SGP (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Irvine, CA
SEC filer status
, Emerging growth company
SEC CIK
1778922
Former names
SpyGlassPharma, Inc. (until Jun 5, 2025); SpyGlass Ophthalmics, Inc. (until Jan 5, 2021)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.